for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innovent Biologics Inc

1801.HK

Latest Trade

50.20HKD

Change

2.50(+5.24%)

Volume

18,200,838

Today's Range

47.35

 - 

51.20

52 Week Range

22.55

 - 

62.90

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
47.70
Open
48.30
Volume
18,200,838
3M AVG Volume
135.93
Today's High
51.20
Today's Low
47.35
52 Week High
62.90
52 Week Low
22.55
Shares Out (MIL)
1,399.73
Market Cap (MIL)
66,767.20
Forward P/E
-45.22
Dividend (Yield %)
--

Next Event

Innovent Biologics Inc Annual Shareholders Meeting

Latest Developments

More

Innovent Biologics Updates On Sales Of Tyvyt (Sintilimab Injection)

Innovent Biologics Says NMPA Granted Marketing Approval For Byvasda (Bevacizumab Biosimilar) In China

Innovent Biologics Says Unit Entered Strategic Collaboration Agreement With Roche Group

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Innovent Biologics Inc

Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company’s main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.

Industry

Biotechnology & Drugs

Contact Info

168

Dongping Street, Suzhou Industrial Park

SUZHOU, JNG

215123

China

http://innoventbio.com

Executive Leadership

De-Chao Yu

Executive Chairman of the Board, President, Chief Executive Officer

Hao Xi Ede

Chief Financial Officer, Executive Director

Qinwei Zhou

Chief Operation Officer

Lok Yee Chan

Joint Company Secretary

Yanju Wang

Joint Company Secretary

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

0.0K

2019

1.0K

2020(E)

2.5K
EPS (CNY)

2018

-17.240

2019

-1.460

2020(E)

-0.933
Price To Earnings (TTM)
--
Price To Sales (TTM)
57.36
Price To Book (MRQ)
11.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
18.19
LT Debt To Equity (MRQ)
17.50
Return on Investment (TTM)
-29.58
Return on Equity (TTM)
-25.78

Latest News

Latest News

BRIEF-Innovent Biologics Says NMPA Granted Marketing Approval For Byvasda (Bevacizumab Biosimilar) In China

* INNOVENT BIOLOGICS INC- NMPA GRANTED MARKETING APPROVAL FOR BYVASDA (BEVACIZUMAB BIOSIMILAR) IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says Unit Entered Strategic Collaboration Agreement With Roche Group

* UNIT ENTERED STRATEGIC COLLABORATION AGREEMENT WITH ROCHE GROUP

BRIEF-Innovent Biologics Enters Strategic Collaboration Agreement With University Of Texas MD Anderson Cancer Center

* INNOVENT BIOLOGICS INC- ENTERED INTO A STRATEGIC COLLABORATION AGREEMENT WITH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

BRIEF-Innovent Biologics Says Study Of TYVYT Met Primary Endpoint Of Overall Survival

* PHASE 2 ORIENT-2 STUDY INVESTIGATING TYVYT MET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Updates On Phase 3 ORIENT-12 Study On Squamous NSCLC

* UPDATES ON PHASE 3 ORIENT-12 STUDY INVESTIGATING TYVYT IN COMBINATION WITH GEMZAR & PLATINUM CHEMOTHERAPY FOR SQUAMOUS NSCLC

BRIEF-Innovent And Eli Lilly Announce NMPA Acceptance Of Supplemental New Drug Application For Sintilimab

* INNOVENT AND ELI LILLY ANNOUNCE NMPA ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR SINTILIMAB IN COMBINATION WITH ALIMTA® (PEMETREXED) Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says China's NMPA Accepted Supplemental New Drug Application For Tyvyt

* CHINA'S NMPA ACCEPTED SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says Revenue Attributable To Sales Of Tyvyt (Sintilimab Injection) In Q1 Around Rmb400 Million

* REVENUE ATTRIBUTABLE TO SALES OF TYVYT (SINTILIMAB INJECTION) IN Q1 AROUND RMB400 MILLION Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics Says U.S. FDA Approves Pemazyre (Pemigatinib) For Metastatic Cholangiocarcinoma

* U.S. FDA APPROVES PEMAZYRE (PEMIGATINIB) FOR ADULTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Innovent Biologics' FY Total Revenue RMB1,047.5 Mln

* FY TOTAL REVENUE WAS RMB1,047.5 MILLION VERSUS RMB9.5 MILLION

Drugmakers slash prices in China to get on reimbursement list

Drugmakers including Roche <ROG.S> and Novartis' <NOVN.S> have agreed to cut the prices of some of their newest drugs by an average of 61% in China in order to get on a national reimbursement scheme list, regulators said.

UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO

* Junshi Biosciences taking advantage of new listing rules in HK

UPDATE 1-China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China biotech Junshi Biosciences seeks up to $414 million in Hong Kong IPO

Chinese biotech company Shanghai Junshi Biosciences is seeking up to $414 million in a Hong Kong initial public offering (IPO), making it the latest company to take advantage of new listing rules to attract early-stage drug developers.

UPDATE 3-China's Innovent Biologics surges in Hong Kong debut

* Market volatility clouding prospects for other IPOs (Adds closing price, analyst comment)

China's Innovent rises 2.3 pct in Hong Kong debut

Innovent Biologics climbed 2.3 percent in a Hong Kong debut closely watched as a test of investor appetite for Chinese biotechs after three rivals saw their shares slide post-listing.

Breakingviews - Hollywood rewrites Hong Kong IPO script

So much for Hong Kong’s Hollywood ending. STX Entertainment, the studio behind “Bad Moms” and Jackie Chan’s “The Foreigner,” allowed its proposed initial public offering in the Asian financial hub to lapse this week. A rocky market is easy to blame, but losing an international...

China's Innovent prices HK IPO near top end, raises $421 million: sources

Innovent Biologics Inc has priced its Hong Kong initial public offering (IPO) near the top of its marketing range to raise $421 million, two people familiar with the matter said, indicating renewed enthusiasm in a sector blighted by falling stocks.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up